Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

211 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The cyclin-G associated kinase (GAK) is a novel mitotic kinase and therapeutic target in diffuse large B-cell lymphoma.
Lightfuss OB, Kumar P, Li L, Shastri T, Newsam AD, Manara P, Alaoui AY, Parets DEH, Younes PA, Chahar D, Arumov A, Coughlin CA, Williams IP, Fattakhov N, Martinez AB, Landgren O, Schurer SC, Lemmon V, Maura F, Bilbao D, Feng Y, Al-Ali H, Schatz JH. Lightfuss OB, et al. Among authors: al ali h. bioRxiv [Preprint]. 2024 Oct 26:2024.10.21.619489. doi: 10.1101/2024.10.21.619489. bioRxiv. 2024. PMID: 39484514 Free PMC article. Preprint.
NCCN guideline-concordant cancer care in Sub-Saharan Africa A population-based multi-country study of five cancers.
Mezger NCS, Seraphin TP, Ballé R, Griesel M, Joko-Fru YW, Hämmerl L, Feuchtner J, Liu B, Zietsman A, Kamaté B, Gnangnon FHR, Gnahatin F, Mboungou DM, Assefa M, Amulen PM, Chesumbai G, Chingonzoh T, Lorenzoni CF, Korir A, Carvalho Santos PS, Mezger JM, Al-Ali HK, Mikolajczyk R, Parkin DM, Jemal A, Kantelhardt EJ. Mezger NCS, et al. Among authors: al ali hk. J Natl Cancer Inst. 2024 Sep 12:djae221. doi: 10.1093/jnci/djae221. Online ahead of print. J Natl Cancer Inst. 2024. PMID: 39269229
Efficacy and safety of fedratinib in patients with myelofibrosis previously treated with ruxolitinib (FREEDOM2): results from a multicentre, open-label, randomised, controlled, phase 3 trial.
Harrison CN, Mesa R, Talpaz M, Al-Ali HK, Xicoy B, Passamonti F, Palandri F, Benevolo G, Vannucchi AM, Mediavilla C, Iurlo A, Kim I, Rose S, Brown P, Hernandez C, Wang J, Kiladjian JJ. Harrison CN, et al. Among authors: al ali hk. Lancet Haematol. 2024 Oct;11(10):e729-e740. doi: 10.1016/S2352-3026(24)00212-6. Epub 2024 Sep 9. Lancet Haematol. 2024. PMID: 39265613 Clinical Trial.
Hematopoietic cell transplantation for older acute myeloid leukemia patients in first complete remission: results of a randomized phase III study.
Niederwieser D, Hasenclever D, Berdel WE, Biemond BJ, Al-Ali H, Chalandon Y, Van Gelder M, Junghanß C, Gahrton G, Hänel M, Hehlmann R, Heinicke T, Hochhaus A, Iacobelli S, Kooy RVM, Kröger N, Janssen J, Jentzsch M, Breywisch F, Mohty M, Masouridi-Levrat S, Ossenkoppele G, Passweg J, Pönisch W, Schetelig J, Schliemann C, Schwind S, Stelljes M, Verdonck LF, Vucinic V, Löwenberg B, Cornelissen J. Niederwieser D, et al. Among authors: al ali h. Haematologica. 2024 Aug 8. doi: 10.3324/haematol.2024.285879. Online ahead of print. Haematologica. 2024. PMID: 39113672 Free article.
MoReLife - real-life data support the potential of momelotinib as a safe and effective treatment option for cytopenic myelofibrosis patients.
Jilg S, Schwaab J, Sockel K, Crodel CC, Brueckl V, Stegelmann F, Jentzsch M, Sasca D, Moyses M, Fuhrmann S, Gundel D, Caduc M, Teichmann LL, Heidel F, Al-Ali HK, Petrides PE. Jilg S, et al. Among authors: al ali hk. Ann Hematol. 2024 Oct;103(10):4065-4077. doi: 10.1007/s00277-024-05908-4. Epub 2024 Jul 29. Ann Hematol. 2024. PMID: 39073589
Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib.
Gagelmann N, Bose P, Gupta V, McLornan DP, Vachhani P, Al-Ali HK, Ali H, Treskes P, Buckley S, Roman-Torres K, Scott B. Gagelmann N, et al. Among authors: al ali hk. Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):796-803. doi: 10.1016/j.clml.2024.06.012. Epub 2024 Jul 2. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39034203 Free article. Clinical Trial.
FRACTION: protocol of a phase II study of Fedratinib and Nivolumab combination in patients with myelofibrosis and resistance or suboptimal response to JAK-inhibitor treatment of the German MPN study group (GSG-MPN).
Isfort S, von Bubnoff N, Al-Ali HK, Becker H, Götze T, le Coutre P, Griesshammer M, Moskwa C, Wohn L, Riedel J, Palandri F, Manz K, Hochhaus A, Döhner K, Heidel FH. Isfort S, et al. Among authors: al ali hk. Ann Hematol. 2024 Aug;103(8):2775-2785. doi: 10.1007/s00277-024-05867-w. Epub 2024 Jul 5. Ann Hematol. 2024. PMID: 38967662 Free PMC article. Clinical Trial.
211 results